MeDex: No Perioperative Dexamethasone in Brain Metastases

Part of paid clinical trials in Louisville, Kentucky.

Sponsor
University of Louisville
Study ID
NCT07044557
Status
Recruiting
Apply to this trial

Conditions

  • Brain Metastases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Withholding perioperative Dexamethasone — OTHER
    Patients will not receive perioperative Dex before, during, and up to 3 weeks after surgery.

Study Details

Perioperative treatment of newly diagnosed cancer patients with brain metastasis without dexamethasone (Dex).

Key Dates

Start date
Aug 1, 2026
Status verified
May 2026
Primary completion
Oct 31, 2027
Completion
Oct 31, 2027

Study Design

Enrollment
35 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER

Arms

  • Experimental: Withholding perioperative dexamethasone
    The safety and feasibility of withholding perioperative dexamethasone (Dex) in newly diagnosed cancer patients undergoing resection of brain metastases (BMs). The primary question is not comparative efficacy, but rather whether it is safe to forgo Dex in this patient population.

Primary Outcome Measure

Dexamethasone Rescue Need [ Time Frame: 4 weeks post operative (+-) 2 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Louisville HospitalLouisvilleKentucky40202
Mechelle Kaufman, BSN
502-852-1513
Akshitkumar Mistry, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Louisville, KY

By research site
University of Louisville Hospital· Louisville, KY

Related Studies